A Phase 3 interventional study of JS002 and JS002 in Primary Hypercholesterolaemia and Mixed Dyslipidemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Dyslipidemias with a site in China — 23 open to participants now, 33 under way, 10 of them phase 3. Dyslipidemias · China.
Among the 75 studies in Dyslipidemias with a site in China, this one is the 14th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2023, is one of 16 in phase 3, reaches primary completion later than 4 of the 32 other live ones, and was the 43rd registered.
1,251 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →23 of the 75 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–75
China Medical University, China · Sites in China
Ages 50–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 12
First in 2008; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 582 is above the median of 100 across 988 interventional studies indexed under Dyslipidemias.
Median enrollment 210 across the 58 interventional studies, 1,000 across the 17 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 75 have an industry lead sponsor. The 10 most frequent:
Shanghai Junshi Bioscience Co., Ltd. is the lead sponsor of 100 studies on the registry; 20 are open to participants now.
Shanghai Junshi Bioscience Co., Ltd. has 1 study filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
8 of the studies in Dyslipidemias with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07350486First Hospital of China Medical UniversityLLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 75 studies in Dyslipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, PK/PD profile, immunogenicity as well as complete delivery of auto-injector by patients of JS002 as monotherapy in patients with primary hypercholesterolaemia and mixed dyslipidemia.
In this study, two dose cohorts(150 mg, 450 mg) are set up, and 582 subjects are planned to be enrolled (randomizedly assigned to JS002 or placebo 150/450 mg group in a 2:1:2:1 ratio).A screening period (≤6 weeks), a double-blind treatment period (12 weeks), an open-label treatment period (40 weeks), and a follow-up period (8 weeks) will be required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JS002 150mg Q2W SC for 52 weeks
Drug: JS002
JS002 450mg Q4W SC for 52 weeks
Drug: JS002
Placebo Q2W SC for 12 weeks, then switch to JS002 150mg Q2W SC for 40 weeks
Drug: Placebo
Placebo Q4W SC for 12 weeks, then switch to JS002 450mg Q4W SC for 40 weeks
Drug: Placebo
JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.
JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.
Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.
Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.
Percent Change From Baseline in LDL-C at Week 12
Percent Change From Baseline in LDL-C at Week 12 in statin intolerance subjects
Time frame: Baseline and week 12
Percent Change From Baseline in LDL-C at Week 12
Percent Change From Baseline in LDL-C at Week 12 in ITT subjects
Time frame: Baseline and week 12
Change From Baseline in LDL-C at Week 12
Change From Baseline in LDL-C at Week 12 in statin intolerance and ITT subjects
Time frame: Baseline and week 12
Percent Change From Baseline in LDL-C at Week 24,52
Percent Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects
Time frame: Baseline and week 24,52
Change From Baseline in LDL-C at Week 24,52
Change From Baseline in LDL-C at Week 24,52 in statin intolerance and ITT subjects
Time frame: Baseline and week 24,52
Percent Change From Baseline in other lipid parameters such as non-HDL-C, ApoB, TC, et al. at Week 12, 24, 52
Percent Change From Baseline in other lipid parameters at Week 12, 24, 52 in statin intolerance and ITT subjects
Time frame: Baseline and week 12, 24, 52
Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL)
Percentage of Participants With LDL-C Less Than 1.8 mmol/L(70 mg/dL) at Week 12, 24, 52 in statin intolerance and ITT subjects
Time frame: Baseline and week 12, 24, 52
Percentage of Participants With Full Administration of JS002
Percentage of Participants With Full Administration of JS002 at Weeks 12, 24, 52 in statin intolerance and ITT subjects
Time frame: Baseline and week 12, 24, 52
Number of Participants with anti-drug antibodies (ADAs)
Serum samples were analyzed for ADA. Positive samples were subsequently tested for neutralizing antibodies.
Time frame: From baseline to week 60
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Sep 2024, 19 months after the start.
Of 62 phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ongericimab
Shanghai Junshi Bioscience Co., Ltd. →